Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

Core Insights - Adaptive Biotechnologies Corporation will report its financial results for Q4 and full year 2024 on February 11, 2025, after market close [1] - A conference call will follow the financial results announcement, starting at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time [1] Company Overview - Adaptive Biotechnologies is a commercial-stage biotechnology company focused on utilizing the adaptive immune system for disease diagnosis and treatment [3] - The company aims to decode the adaptive immune system to enhance its diagnostic and therapeutic capabilities, which have been underutilized [3] - Its proprietary immune medicine platform allows for the translation of the adaptive immune system's genetics with scale, precision, and speed [3] - The company operates in two main business areas: Minimal Residual Disease (MRD) and Immune Medicine, developing products for cancer, autoimmune disorders, and infectious diseases [3] - The goal is to create immune-driven clinical products tailored to individual patients [3]